Showing 781 - 800 results of 33,497 for search '(( 2 fold decrease ) OR ( 50 ((((nn decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 0.84s Refine Results
  1. 781
  2. 782
  3. 783

    Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

    Published 2025
    “…<b>F</b>. Example image of a biocytin-labeled PFC PV interneuron from a control mouse (left) and from cuprizone-treated mouse (right); scale bar: 50 µm. …”
  4. 784
  5. 785
  6. 786
  7. 787

    Six-fold Oxygen-Coordinated Triplet (<i>S</i> = 1) Palladium(II) Moieties Templated by Tris(bipyridine)ruthenium(II) Ions by Fabrice Pointillart (1593232)

    Published 2007
    “…These techniques reveal an unusual 6-fold oxygen environment around the Pd(II) atoms with two short (2.02 Å) and four long (2.17 Å) Pd−O distances. …”
  8. 788

    Six-fold Oxygen-Coordinated Triplet (<i>S</i> = 1) Palladium(II) Moieties Templated by Tris(bipyridine)ruthenium(II) Ions by Fabrice Pointillart (1593232)

    Published 2007
    “…These techniques reveal an unusual 6-fold oxygen environment around the Pd(II) atoms with two short (2.02 Å) and four long (2.17 Å) Pd−O distances. …”
  9. 789
  10. 790
  11. 791
  12. 792
  13. 793
  14. 794

    mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. by Wakiko Iwata (8600457)

    Published 2020
    “…<p>(<b>A</b>) Primary cultured podocytes were isolated from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup> and wild-type controls, followed by western blot analyses of TSC2, phospho-4EBP1, LC3B type II, p62, phospho-ULK1, and β-tubulin. …”
  15. 795
  16. 796

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  17. 797

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  18. 798

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  19. 799

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  20. 800

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”